Physician profile
Eugene T Van
NPI 1952789810
$1,315.15
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $134 · 2021: $137 · 2022: $171 · 2023: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $244.33 | 2019 | |
| Veran Medical Technologies, INC. | $222.17 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $125.11 | 2021 | |
| Mylan Specialty L.P. | $124.98 | 2019 | |
| Abbvie INC. | $113.97 | 2019 | |
| Ironwood Pharmaceuticals, INC | $100.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.66 | 2022 | |
| Linus Health, INC. | $56.45 | 2023 | |
| Insmed, INC. | $50.75 | 2023 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.14 | 2019-2023 | Ofev |
| Glaxosmithkline, LLC. | $45.46 | 2022-2023 | Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $34.34 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.83 | 2022 | |
| Genzyme Corporation | $18.32 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.32 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.